Global pharma major, Lupin Limited (Lupin) has announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS).
Commenting on the appointment, Lupin’s Managing Director, Nilesh Gupta said, “We are delighted to welcome Abdel to our team.”
“He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers”, Nilesh Gupta added.
On his appointment, Abdelaziz Toumi said on LinkedIn, “I’m happy to share that I’m starting a new position as Chief Executive Officer!”
Also Watch: Effective Strategies for Providing Feedback to Underperforming Employees: Marc Effron
LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations (CDMO) business.
Abdel is a seasoned leader with a blend of scientific and commercial skills, and brings over two decades of rich experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia.
His pharmaceutical expertise covers a wide range of fields including commercial operations, sales management, marketing, program management, proposal writing, pricing negotiations, engineering, strategy development & execution, R&D, capacity planning and new product launches.
He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence. Abdel will be based in Switzerland and will spend considerable time in India.
Abdel holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.
Note: We are also on WhatsApp, LinkedIn, Google News, and YouTube, to get the latest news updates, Subscribe to our Channels. WhatsApp– Click Here, Google News– Click Here, YouTube – Click Here, and LinkedIn– Click Here.
